Gastrointestinal Healing: Studying its effects on NSAID-induced gastric lesions, models of IBD (like colitis), or fistulas
(Wegovy, Zepbound, or Foundayo only) Pregnancy and breastfeeding - speak with your provider if you are or plan to be pregnant or breastfeeding, as these GLP-1 agonists should only be used during pregnancy or breastfeeding if the potential benefit outweighs potential risk to the fetus or breastfed infant
Slows Digestion : Tirzepatide slows down food movement through your digestive system
Consultations begin by phone or online request
Per week: 48 swabs (13 per vial + 13 per injection site) 12 weeks: ~75 swabs recommend 1 100-count box 24 weeks: ~150 swabs recommend 2 100-count boxes Protocol Overview Concise summary of the once-weekly regimen
The Chief Scientific Advisor at Novo Nordisk, Lotte Bjerre Knudsen, was the key force who pushed hard to develop GLP-1 drugs for treating obesity and subsequently for Alzheimers